Overview
BPGbio is a clinical-stage biopharmaceutical company using its NAi Interrogative Biology platform, powered by Bayesian causal AI, to discover novel targets from multi-omics data across oncology, rare diseases, and neurology. The company advances a diversified pipeline including BPM31510-IV, a mitochondrial metabolic modulator in Phase 2b for glioblastoma and Phase 2a for pancreatic cancer, targeting tumor metabolism to sensitize to chemotherapy and radiation. Additional programs address squamous cell carcinoma, epidermolysis bullosa, and protein homeostasis via targeted protein degradation.
Frequently asked questions
- What is BPGbio's core technology platform?
- NAi Interrogative Biology, a biology-first Bayesian causal AI platform that analyzes multi-omics data from over 100,000 patients to identify novel drug targets across oncology, rare diseases, and neurology.
- What are the clinical-stage assets in BPGbio's pipeline?
- Lead candidate BPM31510-IV is in Phase 2b for glioblastoma, completed Phase 2a for pancreatic cancer, and explores indications like Primary CoQ10 Deficiency and squamous cell carcinoma; additional programs include BRG399 for immuno-oncology.
- What partnerships support BPGbio's capabilities?
- Partners include Oak Ridge National Labs for supercomputing, Department of Defense, Sanofi, Harvard Medical School, and Advent Health for AI-driven research in oncology, metabolic diseases, and COVID-19 challenges.